Review| Volume 14, ISSUE 2, P85-92, March 2008

Download started.


Apomorphine for the acute treatment of “off” episodes in Parkinson's disease


      Many patients with advanced Parkinson's disease (PD) experience motor complications, which negatively impact quality of life, despite optimized oral therapy. It is important for patients to have a treatment option that may provide rapid relief from “off” episodes. In three pivotal, randomized, placebo-controlled trials, subcutaneous apomorphine was effective in acutely treating “off” episodes, significantly improving Unified Parkinson Disease Rating Scale motor scores and reducing the number of “off” hours per day, with a significantly shorter time to patient-declared onset of relief than placebo. Thus, clinical trial data support the efficacy of intermittent subcutaneous apomorphine as a rapid acute treatment for “off” episodes in advanced PD.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Parkinsonism & Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rajput M.L.
        • Rajput A.H.
        Epidemiology of parkinsonism.
        in: Parkinson's disease: diagnosis and clinical management. Demos, New York2002: 31-40
        • Stacy M.
        Pharmacotherapy for advanced Parkinson's disease.
        Pharmacotherapy. 2000; 20: 8S-16S
        • Ahlskog J.E.
        • Muenter M.D.
        Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.
        Mov Disord. 2001; 16: 448-458
        • Stacy M.
        • Bowron A.
        • Guttman M.
        • Hauser R.
        • Hughes K.
        • Larsen J.P.
        • et al.
        Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
        Mov Disord. 2005; 20: 726-733
        • Anthony J.
        • Spears J.
        • Van Lunen B.
        Implications of motor fluctuations in Parkinson's disease patients on chronic therapy (IMPACT): results from an observational registry.
        Mov Disord. 2005; 20: S146
        • Wilson R.E.
        • Spears J.B.
        • Van Lunen B.E.
        Implications of Motor fluctuations in Parkinson's patients on Chronic Therapy (IMPACT) registry: relationship between Hoehn & Yahr stage and patient- and disease-related characteristics.
        Mov Disord. 2006; 21: S95
        • Stacy M.
        • Spears J.B.
        • Van Lunen B.E.
        Implications of Motor fluctuations in Parkinson's patients on Chronic Therapy (IMPACT) registry: comparison of patient- and physician-reported data.
        Mov Disord. 2006; 21: S92
        • Chapuis S.
        • Ouchchane L.
        • Metz O.
        • Gerbaud L.
        • Durif F.
        Impact of the motor complications of Parkinson's disease on the quality of life.
        Mov Disord. 2005; 20: 224-230
        • Wilson R.E.
        • Silver D.
        • Spears J.B.
        • Van Lunen B.E.
        Implications of Motor fluctuations in Parkinson's patients on Chronic Therapy (IMPACT) registry: quality of life (QOL) data.
        Mov Disord. 2006; 21: S151
        • Swope D.M.
        Rapid treatment of “wearing off” in Parkinson's disease.
        Neurology. 2004; 62: S27-S31
        • Metman L.V.
        • Hoff J.
        • Mouradian M.M.
        • Chase T.N.
        Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
        Mov Disord. 1994; 9: 463-465
        • Pappert E.J.
        • Goetz C.G.
        • Niederman F.
        • Ling Z.D.
        • Stebbins G.T.
        • Carvey P.M.
        Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation.
        Neurology. 1996; 47: 1493-1495
      1. Data on file. Vernalis Pharmaceuticals Inc. Study APO301.

        • Deffond D.
        • Durif F.
        • Tournilhac M.
        Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
        J Neurol Neurosurg Psychiatry. 1993; 56: 101-103
        • Dewey Jr., R.B.
        • Hutton J.T.
        • LeWitt P.A.
        • Factor S.A.
        A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
        Arch Neurol. 2001; 58: 1385-1392
        • Durif F.
        • Deffond D.
        • Tournilhac M.
        Efficacy of sublingual apomorphine in Parkinson's disease.
        J Neurol Neurosurg Psychiatry. 1990; 53: 1105
        • Frankel J.P.
        • Lees A.J.
        • Kempster P.A.
        • Stern G.M.
        Subcutaneous apomorphine in the treatment of Parkinson's disease.
        J Neurol Neurosurg Psychiatry. 1990; 53: 96-101
        • Pietz K.
        • Hagell P.
        • Odin P.
        Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.
        J Neurol Neurosurg Psychiatry. 1998; 65: 709-716
        • Poewe W.
        • Kleedorfer B.
        • Gerstenbrand F.
        • Oertel W.
        Subcutaneous apomorphine in Parkinson's disease.
        Lancet. 1988; 1: 943
        • Stibe C.M.
        • Lees A.J.
        • Kempster P.A.
        • Stern G.M.
        Subcutaneous apomorphine in parkinsonian on–off oscillations.
        Lancet. 1988; 1: 403-406
        • van Laar T.
        • Jansen E.N.
        • Essink A.W.
        • Neef C.
        • Oosterloo S.
        • Roos R.A.
        A double-blind study of the efficacy of apomorphine and its assessment in ‘off’-periods in Parkinson's disease.
        Clin Neurol Neurosurg. 1993; 95: 231-235
      2. Apokyn (apomorphine hydrochloride injection) prescribing information. Morristonw, NJ: Vernalis Pharmaceuticals Inc.; 2004.

        • Koller W.
        APO303 investigators. A double-blind placebo-controlled study of the efficacy of a single dose of subcutaneous apomorphine in Parkinson's disease.
        Neurology. 2004; 62: A329
        • Dewey Jr., R.B.
        Management of motor complications in Parkinson's disease.
        Neurology. 2004; 62: S3-S7
        • Factor S.A.
        Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
        Neurology. 2004; 62: S12-S17
        • Hardie R.J.
        • Lees A.J.
        • Stern G.M.
        On–off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.
        Brain. 1984; 107: 487-506
        • Colosimo C.
        • Merello M.
        • Hughes A.J.
        • Sieradzan K.
        • Lees A.J.
        Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on–off phenomenon.
        J Neurol Neurosurg Psychiatry. 1996; 60: 634-637
        • Steiger M.J.
        • Stocchi F.
        • Bramante L.
        • Ruggieri S.
        • Quinn N.P.
        The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
        Clin Neuropharmacol. 1992; 15: 501-504
        • Merello M.
        • Pikielny R.
        • Cammarota A.
        • Leiguarda R.
        Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.
        Clin Neuropharmacol. 1997; 20: 165-167
        • Steiger M.J.
        • Stocchi F.
        • Carta A.
        • Ruggieri S.
        • Agnoli A.
        • Quinn N.P.
        • et al.
        The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon “off” periods in Parkinson's disease.
        Clin Neuropharmacol. 1991; 14: 241-244
        • Djaldetti R.
        • Melamed E.
        Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.
        Ann Neurol. 1996; 39: 400-404
        • Pfeiffer R.F.
        • Gutmann L.
        • Hull Jr., K.L.
        • Bottini P.B.
        • Sherry J.H.
        • and The APO302 Study Investigators
        Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.
        Parkinsonism Relat Disord. 2007; 13: 93-100
        • Ostergaard L.
        • Werdelin L.
        • Odin P.
        • Lindvall O.
        • Dupont E.
        • Christensen P.B.
        • et al.
        Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.
        J Neurol Neurosurg Psychiatry. 1995; 58: 681-687
        • Dewey Jr., R.B.
        • Maraganore D.M.
        • Ahlskog J.E.
        • Matsumoto J.Y.
        A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
        Mov Disord. 1998; 13: 782-787
        • Montastruc J.L.
        • Rascol O.
        • Senard J.M.
        • Gualano V.
        • Bagheri H.
        • Houin G.
        • et al.
        Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
        Clin Neuropharmacol. 1991; 14: 432-437
        • Hughes A.J.
        • Webster R.
        • Bovingdon M.
        • Lees A.J.
        • Stern G.M.
        Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations.
        Clin Neuropharmacol. 1991; 14: 556-561
        • Ondo W.
        • Hunter C.
        • Almaguer M.
        • Gancher S.
        • Jankovic J.
        Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease.
        Clin Neuropharmacol. 1999; 22: 1-4
        • Kurth M.C.
        Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.
        Drugs Aging. 1997; 10: 332-340
        • Hughes A.J.
        • Bishop S.
        • Kleedorfer B.
        • Turjanski N.
        • Fernandez W.
        • Lees A.J.
        • et al.
        Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
        Mov Disord. 1993; 8: 165-170
        • Bowron A.
        Practical considerations in the use of apomorphine injectable.
        Neurology. 2004; 62: S32-S36